Physician profile
David Mego
NPI 1245224625
$14,240.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $150 · 2021: $218 · 2022: $256 · 2024: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $12,598.46 | 2019 | |
| Abbott Laboratories | $710.87 | 2019-2024 | |
| Boston Scientific Corporation | $383.98 | 2019-2022 | |
| Medtronic, INC. | $152.16 | 2021 | |
| Cook Medical LLC | $117.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $111.91 | 2019 | |
| Medtronic Vascular, INC. | $98.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.25 | 2019 | |
| Chiesi USA, INC. | $11.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.21 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.